These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26433739)

  • 21. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Considerations regarding adherence of anti-osteoporosis therapy.
    Lagari VS; McAninch E; Baim S
    Postgrad Med; 2015 Jan; 127(1):92-8. PubMed ID: 25526234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment strategy of osteoporosis after the bisphosphonates discontinuation.].
    Soen S
    Clin Calcium; 2017; 27(2):273-280. PubMed ID: 28123130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MANAGEMENT OF ENDOCRINE DISEASE: Treatment breaks in long-term management of osteoporosis.
    Langdahl BL
    Eur J Endocrinol; 2019 Jan; 180(1):R29-R35. PubMed ID: 30444721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and safety of long-term bisphosphonate treatment for osteoporosis.].
    Miki T
    Clin Calcium; 2017; 27(2):239-246. PubMed ID: 28123126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate therapy: how long is long enough?
    McClung MR
    Osteoporos Int; 2015 May; 26(5):1455-7. PubMed ID: 25609156
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term outcome of weekly bisphosphonates.
    Rizzoli R
    Clin Orthop Relat Res; 2006 Feb; 443():61-5. PubMed ID: 16462427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoporosis: how long should we treat?
    Sebba A
    Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):502-7. PubMed ID: 18971678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates.
    McClung M
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):735-44. PubMed ID: 17117298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient treatment preferences for osteoporosis.
    Fraenkel L; Gulanski B; Wittink D
    Arthritis Rheum; 2006 Oct; 55(5):729-35. PubMed ID: 17013870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis.
    Murphy-Menezes M
    Clin Ther; 2015 Jul; 37(7):1573-86. PubMed ID: 25913920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.
    Puhaindran ME; Farooki A; Steensma MR; Hameed M; Healey JH; Boland PJ
    J Bone Joint Surg Am; 2011 Jul; 93(13):1235-42. PubMed ID: 21776577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How do bisphosphonates affect fracture healing?
    Kates SL; Ackert-Bicknell CL
    Injury; 2016 Jan; 47 Suppl 1(0 1):S65-8. PubMed ID: 26768295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review: Breaking From Bisphosphonates.
    Seton M
    Arthritis Rheumatol; 2017 Mar; 69(3):494-498. PubMed ID: 27788292
    [No Abstract]   [Full Text] [Related]  

  • 39. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.
    Weil YA; Rivkin G; Safran O; Liebergall M; Foldes AJ
    J Trauma; 2011 Jul; 71(1):186-90. PubMed ID: 21610533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.